These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9883267)

  • 21. [Oral therapy of diabetes].
    Presse Med (1893); 1969 Jun; 77(31):1117-20. PubMed ID: 5793543
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diabetes treatment with the aim of blood glucose normalization].
    Hoizumi M; Yamada Y
    Nihon Rinsho; 2012 Aug; 70(8):1445-50. PubMed ID: 22894087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
    Reboussin DM; Goff DC; Lipkin EW; Herrington DM; Summerson J; Steffes M; Crouse RJ; Jovanovic L; Feinglos MN; Probstfield JL; Banerji MA; Pettitt DJ; Williamson J
    Diabet Med; 2004 Oct; 21(10):1082-9. PubMed ID: 15384954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Insulin secretion and repaglinide].
    Owens D
    Diabetes Metab; 1999 Dec; 25 Suppl 7():17-9. PubMed ID: 10746006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient perceptions of prandial oral therapy for type 2 diabetes.
    Bonneville M; Colgin J; Nalesnick JA; Perez J; Wentz L
    Diabetes Educ; 2001; 27(5):669-77. PubMed ID: 12212016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes.
    Tanenberg RJ
    Curr Med Res Opin; 2004 Apr; 20(4):541-53. PubMed ID: 15119992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
    Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
    J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 33. Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action.
    Hannan JM; Ali L; Rokeya B; Khaleque J; Akhter M; Flatt PR; Abdel-Wahab YH
    Br J Nutr; 2007 Mar; 97(3):514-21. PubMed ID: 17313713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Glinides and glitazones in diabetes treatment. Are they really effective?].
    Parhofer KG; Göke B
    MMW Fortschr Med; 2002 May; 144(18):34-6, 38-9. PubMed ID: 12422705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
    Standl E; Füchtenbusch M
    Diabetologia; 2003 Mar; 46 Suppl 1():M30-6. PubMed ID: 12652356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
    MMW Fortschr Med; 1999 Sep; 141(36):61. PubMed ID: 10904606
    [No Abstract]   [Full Text] [Related]  

  • 39. [The peroral therapy of non-insulin-dependent diabetes mellitus].
    Ametov AS; Granovskaia-Tsvetkova AM
    Ter Arkh; 1994; 66(10):17-9. PubMed ID: 7863436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin treatment improved glucose-induced insulin release in elderly non-insulin-dependent diabetes mellitus, secondary failure to oral hypoglycemic agents.
    Jap TS; Kwok CF; Won JG; Ho LT
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 May; 47(5):320-4. PubMed ID: 1649673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.